250 related articles for article (PubMed ID: 29669520)
21. The effect of metformin on esophageal cancer risk in patients with type 2 diabetes mellitus: a systematic review and meta‑analysis.
Wu HD; Zhang JJ; Zhou BJ
Clin Transl Oncol; 2021 Feb; 23(2):275-282. PubMed ID: 32507907
[TBL] [Abstract][Full Text] [Related]
22. Effect of metformin use on the risk and prognosis of colorectal cancer in diabetes mellitus: a meta-analysis.
Wang Q; Shi M
Anticancer Drugs; 2022 Feb; 33(2):191-199. PubMed ID: 34620743
[TBL] [Abstract][Full Text] [Related]
23. Effect of metformin on the risk of prostate cancer in patients with type 2 diabetes by considering different confounding factors: a meta-analysis of observational studies.
Wang Y; Liu X; Yan P; Tang J; Chen T; Sun Y; Zhou W; Bi Y; Zhang ZJ
Eur J Cancer Prev; 2020 Jan; 29(1):42-52. PubMed ID: 30950925
[TBL] [Abstract][Full Text] [Related]
24. Survival outcomes in endometrial cancer patients according to diabetes: a systematic review and meta-analysis.
McVicker L; Cardwell CR; Edge L; McCluggage WG; Quinn D; Wylie J; McMenamin ÚC
BMC Cancer; 2022 Apr; 22(1):427. PubMed ID: 35439978
[TBL] [Abstract][Full Text] [Related]
25. Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer.
Laskov I; Drudi L; Beauchamp MC; Yasmeen A; Ferenczy A; Pollak M; Gotlieb WH
Gynecol Oncol; 2014 Sep; 134(3):607-14. PubMed ID: 24972190
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of metformin in cancers: An updated meta-analysis based on 80 cohort studies.
Yang J; Yang H; Cao L; Yin Y; Shen Y; Zhu W
Medicine (Baltimore); 2022 Dec; 101(49):e31799. PubMed ID: 36626437
[TBL] [Abstract][Full Text] [Related]
27. Effect of metformin use on the risk and prognosis of ovarian cancer: an updated systematic review and meta-analysis.
Lu MZ; Li DY; Wang XF
Panminerva Med; 2023 Sep; 65(3):351-361. PubMed ID: 31290300
[TBL] [Abstract][Full Text] [Related]
28. Factors associated with survival after relapse in patients with low-risk endometrial cancer treated with surgery alone.
Topfedaisi Ozkan N; Meydanlı MM; Sarı ME; Demirkiran F; Kahramanoglu I; Bese T; Arvas M; Şahin H; Haberal A; Celik H; Coban G; Oge T; Yalcin OT; Akbayır Ö; Erdem B; Numanoğlu C; Özgül N; Boyraz G; Salman MC; Yüce K; Dede M; Yenen MC; Taşkın S; Altın D; Ortaç UF; Aydın Ayık H; Şimşek T; Güngör T; Güngördük K; Sancı M; Ayhan A
J Gynecol Oncol; 2017 Sep; 28(5):e65. PubMed ID: 28657226
[TBL] [Abstract][Full Text] [Related]
29. Metformin is associated with improved survival in endometrial cancer.
Ko EM; Walter P; Jackson A; Clark L; Franasiak J; Bolac C; Havrilesky LJ; Secord AA; Moore DT; Gehrig PA; Bae-Jump V
Gynecol Oncol; 2014 Feb; 132(2):438-42. PubMed ID: 24269517
[TBL] [Abstract][Full Text] [Related]
30. The effect of metformin on gastric cancer in patients with type 2 diabetes: a systematic review and meta-analysis.
Shuai Y; Li C; Zhou X
Clin Transl Oncol; 2020 Sep; 22(9):1580-1590. PubMed ID: 32060719
[TBL] [Abstract][Full Text] [Related]
31. Metformin use and survival outcomes in endometrial cancer: a systematic review and meta-analysis.
Xie W; Li T; Yang J; Shang M; Xiao Y; Li Q; Yang J
Oncotarget; 2017 Sep; 8(42):73079-73086. PubMed ID: 29069850
[TBL] [Abstract][Full Text] [Related]
32. Association of Preadmission Metformin Use and Prognosis in Patients With Sepsis and Diabetes Mellitus: A Systematic Review and Meta-Analysis.
Li Y; Zhao H; Guo Y; Duan Y; Guo Y; Ding X
Front Endocrinol (Lausanne); 2021; 12():811776. PubMed ID: 35002982
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathological characteristics and prognostic value of POLE mutations in endometrial cancer: A systematic review and meta-analysis.
He Y; Wang T; Li N; Yang B; Hu Y
Medicine (Baltimore); 2020 Feb; 99(8):e19281. PubMed ID: 32080141
[TBL] [Abstract][Full Text] [Related]
34. Metformin is associated with survival benefit in pancreatic cancer patients with diabetes: a systematic review and meta-analysis.
Zhou PT; Li B; Liu FR; Zhang MC; Wang Q; Li YY; Xu C; Liu YH; Yao Y; Li D
Oncotarget; 2017 Apr; 8(15):25242-25250. PubMed ID: 28445955
[TBL] [Abstract][Full Text] [Related]
35. Cause-specific mortality in endometrioid endometrial cancer patients with type 2 diabetes using metformin or other types of antidiabetic medication.
Arima R; Hautakoski A; Marttila M; Arffman M; Sund R; Ilanne-Parikka P; Kangaskokko J; Hinkula M; Puistola U; Läärä E
Gynecol Oncol; 2017 Dec; 147(3):678-683. PubMed ID: 29054569
[TBL] [Abstract][Full Text] [Related]
36. Metformin Improves Overall Survival of Colorectal Cancer Patients with Diabetes: A Meta-Analysis.
Meng F; Song L; Wang W
J Diabetes Res; 2017; 2017():5063239. PubMed ID: 28271076
[No Abstract] [Full Text] [Related]
37. Prognostic value of myometrial invasion and TCGA groups of endometrial carcinoma.
Raffone A; Travaglino A; Raimondo D; Neola D; Renzulli F; Santoro A; Insabato L; Casadio P; Zannoni GF; Zullo F; Mollo A; Seracchioli R
Gynecol Oncol; 2021 Aug; 162(2):401-406. PubMed ID: 34088515
[TBL] [Abstract][Full Text] [Related]
38. Metformin Use and Kidney Cancer Survival Outcomes: A Systematic Review and Meta-Analysis.
Nayan M; Punjani N; Juurlink DN; Finelli A; Austin PC; Kulkarni GS; Uleryk E; Hamilton RJ
Am J Clin Oncol; 2019 Mar; 42(3):275-284. PubMed ID: 30663998
[TBL] [Abstract][Full Text] [Related]
39. Prognostic values of pretreatment neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in endometrial cancer: a systematic review and meta-analysis.
Ni L; Tao J; Xu J; Yuan X; Long Y; Yu N; Wu R; Zhang Y
Arch Gynecol Obstet; 2020 Jan; 301(1):251-261. PubMed ID: 31768743
[TBL] [Abstract][Full Text] [Related]
40. Metformin and endometrial cancer risk in Chinese women with type 2 diabetes mellitus in Taiwan.
Tseng CH
Gynecol Oncol; 2015 Jul; 138(1):147-53. PubMed ID: 25913129
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
